A study developed a medical device company that is developing EndoBarrier®for patients with type 2 diabetes and obesity, is pleased to announce the meta-analysis, "Effects of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Type 2 Diabetic Patients with Obesity: A Meta-analysis with Secondary Analysis on Weight Loss and Hormonal Changes. The study was published in the journal Diabetes Care.

The meta-analysis is comprised of 17 published studies that evaluate EndoBarrier outcomes in patients with type 2 diabetes and obesity. The primary outcomes of the meta-analysis were a change in hemoglobin A1c (HbA1c) and homeostatic model assessment of insulin resistance (HOMA-IR). Secondary outcomes changed in weight and change in hormones critical to the regulation of metabolic and bariatric disorders: GIP, GLP-1, PYY, and ghrelin.

"The analysis shows that DJBL is effective at treating diabetes in this patient population with a reduction in HbA1c of 1.3%, and with many patients coming off diabetic medication," said Jirapinyo. "This reduction in HbA1c is significantly better by 0.9% as compared to optimal medical management alone. In addition, this study demonstrates that patients who receive DJBL experience significant improvements in insulin resistance and weight loss, which persist up to at least six months after device removal."

They also highlighted a clinically and statistically significant improvement in insulin resistance. Given a rising pandemic of obesity and diabetes, DJBL may offer a highly effective treatment option for his patient population.

They are pleased to review the results from this comprehensive EndoBarrier meta-analysis that Dr. Jirapinyo and the clinical team at Harvard Medical School and Brigham and Women's Hospital conducted. The results confirm that EndoBarrier produces a significant reduction in HbA1c and weight, significantly reduces insulin resistance and creates a hormonal effect similar in many respects to gastric bypass.

This data clearly shows a very favorable treatment effect with significant treatment durability and a positive benefit-risk profile. This study presents the most comprehensive EndoBarrier meta-analysis we have seen and this type of data is indicative of EndoBarrier's highly impactful clinical utility.